Ace the Case: DOACs and Patients with Malignancies (Part 3 of 3)

Overview

Provided by

Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Release date: 07/27/2022
Expiration date: 07/27/2023
Estimated time to complete: 0.25 hours
Activity URL: https://cme.healio.com/cardiology/20220711/3-anti-coagulation

Activity Description

Direct acting oral anti-coagulants (DOACs) are a newer class of medications with emerging clinical recommendations and evidence for safe use. Cardiologists and pharmacists have key roles to play as part of the care team to help ensure efficacy and safety of DOACs within the severely ill patient population.

Recommendations and evidence surrounding the use of DOACs in special medical populations continue to evolve to address concerns of use in patients with obesity, renal disease, active malignancy, and older adults. The interprofessional care team has a key role in formulating anticoagulation regimens that are appropriate for individual patients. Team members, therefore, would benefit from education on the efficacy and safety of DOACs in medically vulnerable populations.

Faculty Educators

Maya R. Chilbert, PharmD, BCCP
Clinical Assistant Professor
University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY

Elaine M. Hylek, MD, MPH
Professor, Boston University School of Medicine, Boston, MA
Attending, Boston Medical Center, Boston, MA

Target Audience

This activity has been designed to meet the educational needs of physicians and pharmacists. Other healthcare providers may also participate.

Learning Objectives

After participating in the activity, learners should be better able to:

• Identify the indications, doses, and pharmacokinetic properties of direct acting oral anti-coagulants (DOAC’s) and compare the risk of bleeding among DOACs.
• Select appropriate anticoagulation therapy for individual patients based on concomitant disease and medication use.
• Design anticoagulation regimens for transitions between anticoagulants and for use in combinations with other interacting medications while relying on the interprofessional care team.

Accreditation and Credit Designation

In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pharmacists

This activity provides 0.25 ACPE contact hours (0.025 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-22-050-H01-P.

Disclosures

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educators

Maya R. Chilbert, PharmD, BCCP
No financial disclosures to report with ineligible companies.

Elaine M. Hylek, MD, MPH
Dr. Hylek discloses the following with ineligible companies:
Advisory Board/Consultant: Bayer, Boehringer Ingelheim, Pfizer
Grant/Research Support: Abbott Laboratories, Anthos Therapeutics, Bristol Myers Squibb, Janssen Pharmaceuticals, Inc, Medtronic

Independent Clinical Reviewer

Stephanie J. Seyse, PharmD, BCPS, FASHP, CACP
Dr. Seyse reports the following disclosure with ineligible companies:
Shareholder: GlaxoSmithKline, AbbVie

Planning Committee

John JD. Juchniewicz, MCIS, CHCP, FACEHP; Wendy Gloffke, PhD; and Paul J. Miniter, MS, American Academy of CME: No relevant financial relationships with ineligible companies to disclose.

This activity includes the mention of investigational drugs.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CE credit and for physicians to be eligible to earn ABIM MOC points for your participation, please complete the post-assessment and program evaluation. Your certificate can be printed immediately.

For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

CLAIMING MOC POINTS: If you intend to claim MOC points for your participation, you will need to provide your unique ABIM ID when completing the activity evaluation. Physicians who do not know their ABIM ID can log in to the ABIM website at https://www.abim.org — your ABIM ID will appear next to your name.

By claiming MOC points, you are agreeing to have your participation completion information to be shared with the ACCME and the ABIM. Your points will be automatically submitted to the ABIM on your behalf; please allow 6-8 weeks for your points to display on the ABIM website.

Hardware/Software Requirements

Please ensure the computer you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2022. This accredited continuing education activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).